BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended September 30, 2025 and highlighted recent developments. “During our third quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “We expect to initiate our Phase 2b clinical study of IKT-001, our prodrug of imatinib mesylate, in PAH during the fourth quarter of 2025.” Recent Developments:Advancement of IKT-001 as a therapy in PAH:The proposed Phase 2b IMPROVE-PAH trial is...

Third Quarter 2025 HighlightsXBP Europe Holdings, Inc. (“XBP Europe”) finalized the acquisition of Exela Technologies BPA, LLC (“Exela BPA”) and changed its name to XBP Global Holdings, Inc. on July 29, 2025 XBP Europe issued approximately 81.8 million shares for an equity valuation of the combined company of $585.7 million, or $4.98/share     Reported revenue1 totaled $209.1 million, a decline of 10.4% year-over-year Combined Pro Forma Revenue2 totaled $220.4 million, a decline of 18.1% year-over-year Gross margin on a reported basis was 22.0%, a 310 basis point increase year-over-year Pro Forma Gross Margin2 of 21.9%, a 190 basis point increase year-over-year Pro Forma Adjusted EBITDA2,3 of $24.7 million, an increase of 7.4% year-over-yearIRVING, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) — XBP Global Holdings, Inc. (“XBP Global”...

– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the third quarter of 2025. Corporate Highlights from 3Q 2025Announced second partner order for FemBloc in Europe Announced FDA IDE approval to continue enrollment in final phase of the FINALE pivotal trial for FemBloc Announced a definitive agreement for the issuance of $12 million in secured convertible notes and accompanying warrants for total potential funding of $58 million, if all warrants are...

ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) — Atlantic American Corporation (Nasdaq- AAME) today reported net income of $0.6 million, or $0.02 per diluted share, for the three month period ended September 30, 2025, compared to net loss of ($2.0) million, or ($0.10) per diluted share, for the three month period ended September 30, 2024. The Company had net income of $4.7 million, or $0.22 per diluted share, for the nine month period ended September 30, 2025, compared to net loss of ($4.7) million, or ($0.24) per diluted share, for the nine month period ended September 30, 2024. The increase in net income for the three month and nine month periods ended September 30, 2025 was primarily the result of increases in premium revenue within the automobile liability, inland marine and automobile physical damage lines of business in the property...

BETHLEHEM, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) — On November 13, 2025, Embassy Bancorp, Inc. (OTCQX: EMYB) (the “Company”) filed its Quarterly Report on Form 10-Q for the period ended September 30, 2025, a copy of which can be found at https://investors.embassybank.com/sec-filings/documents/default.aspx. Highlights of the filing, which includes consolidated financial information of the Company and Embassy Bank For the Lehigh Valley (the “Bank”), the Company’s wholly owned subsidiary, include:Cash and cash equivalents on hand of $108.0 million at September 30, 2025, or 6.1% of total assets. Deposits of $1.62 billion at September 30, 2025, an increase of $67.6 million, or 4.4%, from $1.55 billion at December 31, 2024. The Company does not have any brokered deposits. Short term borrowings of $15.6 million at December 31, 2024, were...

WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, 2025, highlighting continued capital-efficient execution at a time when sustainability has become what the Company believes a defining challenge for the biotechnology industry. Tevogen reported a loss from operations calculated in accordance with U.S. GAAP of $5.7 million for the three months ended September 30, 2025, a reduction of 6% as compared to the three months ended September 30, 2024. The Company reported a 51% reduction in operating loss, totaling $21.5 million for the nine months ended September 30, 2025, compared to the same period in 2024. Tevogen Bio Holdings Inc. Unaudited Consolidated Statements of Operations    Three...

PHOENIX, Nov. 14, 2025 (GLOBE NEWSWIRE) — QuoteMedia, Inc. (OTCQB: QMCI), a leading provider of market data and financial applications, today announced financial results for the quarter ended September 30, 2025, reporting 10% year-over-year revenue growth to $5.2 million. The Company also secured several major new contracts expected to contribute meaningfully to revenue beginning in the third quarter. QuoteMedia provides banks, brokerage firms, private equity firms, financial planners and sophisticated investors with a more economical, higher quality alternative source of stock market data and related research information. We compete with several larger legacy organizations and a modest community of other smaller companies.  QuoteMedia provides comprehensive market data services, including streaming data feeds, on-demand request-based...

Key third quarter reported data points:Revenue of $16.4 million, +3.5% vs. Q3 2024 GAAP net income from continuing operations of $651 thousand vs. $861 thousand in Q3 2024 GAAP net income from continuing operations per fully diluted share of $0.012 vs. $0.017 in Q3 2024 Non-GAAP adjusted EBITDA of $321 thousand vs. $1 million in Q3 2024 Subsequent Event: Announced new leadership in CEO Gary SchubertBROADVIEW, Ill., Nov. 14, 2025 (GLOBE NEWSWIRE) — Innovative Food Holdings, Inc. (OTCQB: IVFH) (“we,” “our,” “us,” “IVFH” or the “Company”), a national seller of gourmet specialty foods to professional chefs, today announced financial results for the third quarter ended September 30, 2025. Gary Schubert, Chief Executive Officer of IVFH, remarked, “In Q3 2025, revenue from continuing operations increased by 3.5% year-over-year, primarily...

TROY, Mich., Nov. 14, 2025 (GLOBE NEWSWIRE) — Viper Networks (OTCPK: VPER) released its third quarter 2025 financial statements, improving quarter-over-quarter top line revenue, increasing EBITDA and continuing to reduce debt. Revenues from the quarter rose to $1.562 million, increasing from $1.307 million in the first quarter of 2025 (the first full quarter after the acquisition of the telecommunications business unit). EBITDA (non-GAAP) for the nine-months ended September 30, 2025 increased to $103,387, as compared to an EBITDA loss of $288,418 for the same period in 2024. The growth was primarily due to organic increases in the Over-the-Top (“OTT”) business unit. Operating losses decreased to $58,771, from $314,813 in the same period in 2024. The operating loss was primarily due to non-cash expenses, including depreciation and...

Strategic Investments in People and Technology Drive Sustained Growth, $80M+ Contract Backlog, and Expanding Pipeline MCLEAN, Va., Nov. 14, 2025 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leader in identity-centric cybersecurity solutions and AI-powered IT infrastructure, today announced its financial results for the third quarter ended September 30, 2025, alongside continued revenue acceleration into the fourth quarter of 2025. Cycurion has strategically invested in high-caliber talent and technology and its strategy is delivering compounding returns with a contract backlog exceeding $80 million, a new data modernization contract for SLG Innovation, Inc. (“SLG”) and a forecasted first quarter of 2026 run-rate revenue of $4.2 million. “The third quarter of 2025 marked a pivotal...